A RANDOMIZED, PLACEBO-CONTROLLED STUDY TO ASSESS THE SAFETY, TOLERABILITY, PHARMACOKINETICS, AND EFFECTS ON HETEROTOPIC BONE FORMATION OF REGN2477 IN PATIENTS WITH FIBRODYSPLASIA OSSIFICANS PROGRESSIVA

Registry ID

R2477-FOP-1623

Source registry

HEALTH_CANADA

Status

Pending

Study type

INTERVENTIONAL

Sponsor

REGENERON PHARMACEUTICALS INC

Last update

2018-08-10

Conditions

• FIBRODYSPLASIA OSSIFICANS PROGRESSIVA (FOP)

Related clinical trials

• A PHASE 2, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY TO EVALUATE THE EFFICACY, SAFETY, AND TOLERABILITY OF INCB000928 IN PARTICIPANTS WITH FIBRODYSPLASIA OSSIFICANS PROGRESSIVA

View on source registry